715 related articles for article (PubMed ID: 31822751)
1. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells.
Herrera L; Santos S; Vesga MA; Anguita J; Martin-Ruiz I; Carrascosa T; Juan M; Eguizabal C
Sci Rep; 2019 Dec; 9(1):18729. PubMed ID: 31822751
[TBL] [Abstract][Full Text] [Related]
2. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
[TBL] [Abstract][Full Text] [Related]
3. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
4. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E; Marin D; Banerjee P; Macapinlac HA; Thompson P; Basar R; Nassif Kerbauy L; Overman B; Thall P; Kaplan M; Nandivada V; Kaur I; Nunez Cortes A; Cao K; Daher M; Hosing C; Cohen EN; Kebriaei P; Mehta R; Neelapu S; Nieto Y; Wang M; Wierda W; Keating M; Champlin R; Shpall EJ; Rezvani K
N Engl J Med; 2020 Feb; 382(6):545-553. PubMed ID: 32023374
[TBL] [Abstract][Full Text] [Related]
5. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.
Quintarelli C; Sivori S; Caruso S; Carlomagno S; Falco M; Boffa I; Orlando D; Guercio M; Abbaszadeh Z; Sinibaldi M; Di Cecca S; Camera A; Cembrola B; Pitisci A; Andreani M; Vinti L; Gattari S; Del Bufalo F; Algeri M; Li Pira G; Moseley A; De Angelis B; Moretta L; Locatelli F
Leukemia; 2020 Apr; 34(4):1102-1115. PubMed ID: 31745215
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
Brudno JN; Somerville RP; Shi V; Rose JJ; Halverson DC; Fowler DH; Gea-Banacloche JC; Pavletic SZ; Hickstein DD; Lu TL; Feldman SA; Iwamoto AT; Kurlander R; Maric I; Goy A; Hansen BG; Wilder JS; Blacklock-Schuver B; Hakim FT; Rosenberg SA; Gress RE; Kochenderfer JN
J Clin Oncol; 2016 Apr; 34(10):1112-21. PubMed ID: 26811520
[TBL] [Abstract][Full Text] [Related]
8. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
9. Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies.
Luanpitpong S; Poohadsuan J; Klaihmon P; Issaragrisil S
J Immunol Res; 2021; 2021():5562630. PubMed ID: 34337077
[TBL] [Abstract][Full Text] [Related]
10. Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
Nagle K; Tafuto B; Palladino Kim L; Parrott JS
Med Oncol; 2018 Sep; 35(11):144. PubMed ID: 30206753
[TBL] [Abstract][Full Text] [Related]
11. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
[TBL] [Abstract][Full Text] [Related]
12. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
13. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
[TBL] [Abstract][Full Text] [Related]
14. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
15. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
Yang N; Zhang C; Zhang Y; Fan Y; Zhang J; Lin X; Guo T; Gu Y; Wu J; Gao J; Zhao X; He Z
J Transl Med; 2024 Mar; 22(1):274. PubMed ID: 38475814
[TBL] [Abstract][Full Text] [Related]
16. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
17. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
18. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
19. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]